Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0E1WH
|
||||
| Former ID |
DIB009065
|
||||
| Drug Name |
LY-2608204
|
||||
| Synonyms |
Glucokinase activator (type 2 diabetes), Eli Lilly
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Type 2 diabetes [ICD9: 250; ICD10:E11] | Phase 2 | [1] | ||
| Company |
Eli Lilly & Co
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C28H37N3O3S3
|
||||
| Canonical SMILES |
C1CCC(CC1)C2CC2(C3=CC=C(C=C3)S(=O)(=O)C4CC4)C(=O)NC5=NC<br />=C(S5)SCCN6CCCC6
|
||||
| InChI |
1S/C28H37N3O3S3/c32-26(30-27-29-19-25(36-27)35-17-16-31-14-4-5-15-31)28(18-24(28)20-6-2-1-3-7-20)21-8-10-22(11-9-21)37(33,34)23-12-13-23/h8-11,19-20,23-24H,1-7,12-18H2,(H,29,30,32)/t24-,28-/m0/s1
|
||||
| InChIKey |
QIIVJLHCZUTGSD-CUBQBAPOSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID | |||||
| Target and Pathway | |||||
| Target(s) | Glucokinase | Target Info | Activator | [2] | |
| KEGG Pathway | Glycolysis / Gluconeogenesis | ||||
| Galactose metabolism | |||||
| Starch and sucrose metabolism | |||||
| Amino sugar and nucleotide sugar metabolism | |||||
| Butirosin and neomycin biosynthesis | |||||
| Metabolic pathways | |||||
| Biosynthesis of antibiotics | |||||
| Carbon metabolism | |||||
| Insulin signaling pathway | |||||
| Insulin secretion | |||||
| Prolactin signaling pathway | |||||
| Glucagon signaling pathway | |||||
| Type II diabetes mellitus | |||||
| Maturity onset diabetes of the young | |||||
| Central carbon metabolism in cancer | |||||
| Pathway Interaction Database | FOXA2 and FOXA3 transcription factor networks | ||||
| HIF-1-alpha transcription factor network | |||||
| PathWhiz Pathway | Nucleotide Sugars Metabolism | ||||
| Starch and Sucrose Metabolism | |||||
| Galactose Metabolism | |||||
| Trehalose Degradation | |||||
| Reactome | Regulation of gene expression in beta cells | ||||
| Glucose transport | |||||
| Glycolysis | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Glycolysis and Gluconeogenesis | |||||
| MAPK Signaling Pathway | |||||
| Regulation of beta-cell development | |||||
| Metabolism of carbohydrates | |||||
| Hexose transport | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01408095) A Study in Patients With Type 2 Diabetes. U.S. National Institutes of Health. | ||||
| REF 2 | Clinical pipeline report, company report or official report of Eli Lilly. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.